The expression pattern of PFKFB3 enzyme distinguishes between induced-pluripotent stem cells and cancer stem cells.
Induced pluripotent stem cells (iPS) have become crucial in medicine and biology. Several studies indicate their phenotypic similarities with cancer stem cells (CSCs) and a propensity to form tumors. Thus it is desirable to identify a trait which differentiates iPS populations and CSCs. Searching for such a feature, in this work we compare the restriction (R) point-governed regulation of cell cycle progression in different cell types (iPS, cancer, CSC and normal cells) based on the expression profile of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase3 (PFKFB3) and phosphofructokinase (PFK1). Our study reveals that PFKFB3 and PFK1 expression allows discrimination between iPS and CSCs. Moreover, cancer and iPS cells, when cultured under hypoxic conditions, alter their expression level of PFKFB3 and PFK1 to resemble those in CSCs. We also observed cell type-related differences in response to inhibition of PFKFB3. This possibility to distinguish CSC from iPS cells or non-stem cancer cells by PFKB3 and PFK1 expression improves the outlook for clinical application of stem cell-based therapies and for more precise detection of CSCs.
Department of Clinical and Experimental Medicine, Division of Cell Biology, Linköping University, Linköping, Sweden.|Integrative Regenerative Medicine Center (IGEN), Linköping University, Linköping, Sweden.|Institute of Automatic Control, Silesian University of Technology, Akademicka 16, Gliwice, Poland.
Artur
A
Cieślar-Pobuda
Department of Clinical and Experimental Medicine, Division of Cell Biology, Linköping University, Linköping, Sweden.
Mayur Vilas
MV
Jain
Integrative Regenerative Medicine Center (IGEN), Linköping University, Linköping, Sweden.|Experimental Plastic Surgery, IKE, Linköping University, Linköping, Sweden.|Department of Plastic Surgery, County of Östergötland, Linköping, Sweden.
Gunnar
G
Kratz
Institute of Automatic Control, Silesian University of Technology, Akademicka 16, Gliwice, Poland.
Joanna
J
Rzeszowska-Wolny
Department of Human Anatomy and Cell Science, University of Manitoba, Manitoba, Canada.
Saeid
S
Ghavami
Department of Clinical and Experimental Medicine, Division of Cell Biology, Linköping University, Linköping, Sweden.|Integrative Regenerative Medicine Center (IGEN), Linköping University, Linköping, Sweden.
Emilia
E
Wiechec
D000444:Aldehyde Dehydrogenase / Q000378:metabolism; D002453:Cell Cycle / Q000235:genetics; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D020869:Gene Expression Profiling; D006801:Humans; D015151:Immunoblotting; D057026:Induced Pluripotent Stem Cells / Q000378:metabolism*; D018613:Microscopy, Confocal; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D010732:Phosphofructokinase-1 / Q000235:genetics; D025481:Phosphofructokinase-2 / Q000235:genetics* / Q000378:metabolism; D034622:RNA Interference; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018874:Spheroids, Cellular / Q000378:metabolism
D000444:Aldehyde Dehydrogenase; C107345:PFKFB3 protein, human; D025481:Phosphofructokinase-2; D010732:Phosphofructokinase-1
PFK1; PFKFB3; R-point; cancer stem cells; induced pluripotent stem cells